8-K: INVO Bioscience Secures $275,000 Promissory Note with Conversion and Warrant Options

INVO Bioscience has entered into a securities purchase agreement, securing a $275,000 promissory note along with warrants and shares, aimed at bolstering working capital.

Summary

• INVO Bioscience has obtained a $275,000 promissory note from FirstFire Global Opportunities Fund, with an initial purchase price of $250,000 and a $25,000 original issue discount.
• The note carries a 12% annual interest rate, with the first year's interest of $33,000 guaranteed and earned upfront.
• The maturity date is set 12 months from the issue date, April 5, 2024.
• The note is convertible into common stock at a price of $1.00 per share, subject to adjustments for stock splits, dividends, and other similar events.
• The holder's conversion rights are limited to ensure they do not exceed 4.99% beneficial ownership of the company's outstanding common stock.
• In addition to the note, the company issued warrants to purchase 229,167 shares at $1.20 per share and 500,000 shares at $0.01 per share, along with 50,000 commitment shares.
• The company may prepay the note at 110% of the outstanding principal plus accrued interest.
• If the company receives over $1,500,000 in cash proceeds from any source, or $1,000,000 from a public offering, the note holder can demand up to 100% of those proceeds be used to repay the note.
• The agreement includes various covenants restricting the company's ability to declare dividends, sell assets, or engage in affiliate transactions without the note holder's consent.
• Events of default include failure to pay principal or interest, breaches of covenants, bankruptcy, and failure to comply with SEC reporting requirements.

Sentiment

Score: 4

Explanation: The document indicates a necessary capital raise, but the terms are not particularly favorable for the company, with high interest rates and restrictive covenants. The potential for dilution is also a concern.

Positives

• The company has secured immediate funding of $250,000 with a potential for further capital through conversion of the note and exercise of warrants.
• The guaranteed interest payment provides a degree of certainty for the lender.
• The conversion feature allows the lender to participate in potential upside if the company's stock price increases.
• The prepayment option provides flexibility for the company to manage its debt.
• The ability to demand repayment from future proceeds provides a safety net for the lender.

Negatives

• The company is subject to various restrictions on its operations and financial activities.
• The conversion of the note and exercise of warrants could lead to significant dilution of existing shareholders.
• The high interest rate of 12% and the 10% prepayment premium could be costly for the company.
• The potential for the note holder to demand repayment from future proceeds could limit the company's financial flexibility.
• The company is subject to a number of events of default that could trigger immediate repayment of the note.

Risks

• The company's ability to meet its financial obligations under the note is dependent on its future performance.
• The conversion of the note and exercise of warrants could significantly dilute existing shareholders.
• The company's operations are subject to various restrictions that could limit its growth potential.
• The company is subject to a number of events of default that could trigger immediate repayment of the note.
• The company may need to seek shareholder approval to issue more shares than the Exchange Cap.

Future Outlook

The company intends to use the proceeds for working capital and general corporate purposes, including a potential registered offering of its common stock, acquisitions, and business development. The company is also required to seek shareholder approval to issue more shares than the Exchange Cap.

Industry Context

This type of financing is common for small-cap companies seeking to raise capital. The use of convertible notes and warrants is a way to attract investors who are willing to take on more risk in exchange for potential upside.

Comparison to Industry Standards

• The terms of this financing, including the interest rate, conversion price, and warrant coverage, are within the typical range for similar transactions in the small-cap market.
• The 12% interest rate is relatively high, reflecting the risk associated with investing in a small-cap company.
• The conversion price of $1.00 per share is a common structure, allowing the lender to convert their debt into equity at a fixed price.
• The warrants provide additional upside potential for the lender, as they can purchase shares at a set price in the future.
• The 4.99% beneficial ownership limitation is a standard provision to prevent the lender from gaining too much control of the company.

Stakeholder Impact

• Shareholders may experience dilution due to the conversion of the note and exercise of warrants.
• Employees may be impacted by the company's financial performance and operational restrictions.
• Customers and suppliers may be affected by the company's ability to operate and grow.
• Creditors may be impacted by the company's ability to repay its debts.

Next Steps

• The company needs to use the proceeds for working capital and general corporate purposes.
• The company needs to seek shareholder approval to issue more shares than the Exchange Cap.
• The company needs to comply with the reporting requirements of the 1934 Act.
• The company needs to maintain the listing and trading of its Common Stock on the Principal Market.

Key Dates

Keywords

promissory note, conversion, warrants, financing, capital raise, securities purchase agreement, common stock, dilution, debt, investment